The EU Commission clears a merger subject to remedies in the pharmaceutical sector (Pfizer / Hospira)

MERGERS: COMMISSION APPROVES ACQUISITION OF HOSPIRA BY PFIZER * The European Commission has approved the proposed acquisition of Hospira by Pfizer under the EU Merger Regulation. Both companies are US based and active globally in the development and marketing of human pharmaceuticals. The approval is conditional on Pfizer divesting certain sterile injectable drugs, as well as its infliximab biosimilar drug, which is currently under development. The Commission expressed concerns that the merged entity would have faced insufficient competitive pressure from the remaining players in the corresponding markets, with a risk of price rises and discontinuation of the development of Pfizer's infliximab biosimilar drug. The commitments offered by the companies address these by removing the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission clears a merger subject to remedies in the pharmaceutical sector (Pfizer / Hospira), 4 August 2015, e-Competitions August 2015, Art. N° 74864

Visites 239

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues